Global Blood Therapeutics, Inc.
GBT was delisted on the 4th of October, 2022.
59 hedge funds and large institutions have $1.12B invested in Global Blood Therapeutics, Inc. in 2015 Q3 according to their latest regulatory filings, with 59 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRV
Third Rock Ventures
Boston,
Massachusetts
|
+$696M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$208M |
| 3 |
PA
Perceptive Advisors
New York
|
+$43.5M |
| 4 |
DM
Deerfield Management
New York
|
+$42M |
| 5 |
PHS
PFM Health Sciences
San Francisco,
California
|
+$35.8M |
Top Sellers
GBT Hedge Fund Activity: Q3 2015 in Review
59 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Global Blood Therapeutics, Inc. (GBT) for Q3 2015, worth a combined $1.12B.
Buyers outnumbered sellers: 59 funds opened new GBT positions and 0 closed out — a net gain of 59 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Third Rock Ventures, opening a new position worth an estimated $696M.
- 59 institutional investors held Global Blood Therapeutics, Inc. (GBT) as of Q3 2015, up from 0 in Q2 2015.
- Funds reported $1.12B of Global Blood Therapeutics, Inc. stock for Q3 2015.
- 59 funds opened new Global Blood Therapeutics, Inc. positions in Q3 2015 and 0 closed out, a net change of +59 holders.
- The largest Global Blood Therapeutics, Inc. buyer in Q3 2015 was Third Rock Ventures, an estimated $696M added.
Based on aggregated 13F filings for Q3 2015.